Coccidioidomycosis in Persons Infected with HIV Type 1

Mayer, Kenneth H.; Ampel, Neil M.
October 2005
Clinical Infectious Diseases;10/15/2005, Vol. 41 Issue 8, p1174
Academic Journal
Coccidioidomycosis is a recognized opportunistic infection among persons infected with human immunodeficiency virus (HIV). Early in the HIV epidemic, most cases presented as overwhelming diffuse pulmonary disease with a high mortality rate. Although these cases are still seen, patients without significant immunodeficiency frequently present with a community-acquired pneumonia syndrome. Diagnosis can be established by cytological staining, culture, or serologic testing. All patients with HIV infection and symptomatic coccidioldomycosis should be treated with antifungal therapy. Severe cases frequently require a combination of therapy with amphotericin B and a triazole antifungal. Therapy for at least 1 year is recommended, but for patients with a focal pulmonary infection and peripheral blood CD4 lymphocyte counts of >250 cells/μt, it may be reasonable to stop therapy after this time. Other manifestations of coccidioidomycosis require prolonged therapy, and life-long treatment is recommended for persons with meningitis.


Related Articles

  • Role of upper endoscopy in diagnosing opportunistic infections in human immunodeficiency virus-infected patients. Werneck-Silva, Ana Luiza; Prado, Ivete Bedin; Montiel-Jarquin, Alvaro // World Journal of Gastroenterology;3/7/2009, Vol. 15 Issue 9, p1050 

    Highly active antiretroviral therapy (HAART) has dramatically decreased opportunistic infections (OIs) in human immunodeficiency virus (HIV)-infected patients. However, gastrointestinal disease continues to account for a high proportion of presenting symptoms in these patients. Gastrointestinal...

  • Prophylaxis in HIV infection: New guidelines issued. D'Epiro, Nancy Walsh // Patient Care;10/15/1997, Vol. 31 Issue 16, p14 

    Focuses on recommendations of the working group of the United States Public Health Service and the Infectious Diseases Society of America on prophylaxis against opportunistic infections in HIV-infected patients. Recommendations on pneumocystis carinii pneumonia (PCP), toxoplasmic encephalitis,...

  • Discontinuing prophylaxis against recurrent opportunistic infections in HIV-infected persons: a victory in the era of HAART. Kaplan, Jonathan E.; Masur, Henry; Holmes, King K. // Annals of Internal Medicine;8/20/2002, Vol. 137 Issue 4, p285 

    Editorial. Comments on Ole Kirk and colleagues' (2002) study of the discontinuation of chemoprophylaxis after episodes of opportunistic infections in HIV-infected persons. Lack of data about which patients can most safely discontinue secondary prophylaxis; Minimum duration of long-term...

  • Can Maintenance Therapy for Opportunistic Infections in HIV-Infected People Be Stopped Safely?  // Annals of Internal Medicine;8/20/2002, Vol. 137 Issue 4, pI-34 

    Presents a summary of the study on the discontinuation of chemoprophylaxis for opportunistic infections in HIV-infected people. Objective of the study; Findings of the researchers; Limitations and implications of the study.

  • Coccidioidomycosis in Human Immunodeficiency Virus-Infected Persons in Arizona, 1994-1997: Incidence, Risk Factors, and Prevention. Woods, Christopher W.; McRill, Cheryl; Plikaytis, Brian D.; Rosenstein, Nancy E.; Mosley, David; Boyd, Denise; England, Bob; Perkins, Bradley A.; Ampel, Neil M.; Hajjeh, Rana A. // Journal of Infectious Diseases;4/1/2000, Vol. 181 Issue 4 

    Examines the incidence and prevention of coccidioidomycosis among HIV infected patients in Arizona. Association of oropharyngeal or esophageal candidiasis with coccidioidomycosis increased risk; Etiology of coccidioidomycosis; Effectiveness of azole in preventing systemic mycoses.

  • Considerations for Patients with Established HIV Infection.  // MMWR: Morbidity & Mortality Weekly Report;5/17/2002 Supplement RR-7, Vol. 51 Issue 19, p5 

    Discusses the considerations for patients with established HIV infection. Clinical categories of patients with HIV infection; Evaluation that should be performed before initiating therapy for any patient; Routine tests that are relevant to preventing opportunistic infections.

  • Prophylaxis of opportunistic infections in the era of potent antiretroviral therapy: An update. Aberg, Judith A. // Formulary;May99, Vol. 34 Issue 5, p418 

    Focuses on the prevalence of prophylaxis on HIV-infected persons in the United States. Impact of highly antiretroviral therapy (HAART) on the incidence of opportunistic infections (OI) among HIV-infected patients; Association of HAART in AIDS-related mortality and days of hospitalization;...

  • Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Murphy, Edward L.; Collier, Ann C.; Kalish, Leslie A.; Assmann, Susan F.; Para, Michael F.; Flanigan, Timothy P.; Kumar, Princy N.; Mintz, Letty; Wallach, Frances R.; Nemo, George J.; Murphy, E L; Collier, A C; Kalish, L A; Assmann, S F; Para, M F; Flanigan, T P; Kumar, P N; Mintz, L; Wallach, F R; Nemo, G J // Annals of Internal Medicine;7/3/2001, Vol. 135 Issue 1, p17 

    Background: Mortality and morbidity related to AIDS have decreased among HIV-infected patients taking highly active anti-retroviral therapy (HAART), but previous studies may have been confounded by other changes in treatment.Objective: To assess the benefit of HAART in...

  • CDC revises guidelines on preventing opportunistic infections in HIV. Lucas, Beverly D. // Patient Care;11/15/1999, Vol. 33 Issue 18, p16 

    Reports the revision of Centers for Disease Control and Prevention guidelines for the prevention of opportunistic infections (OI) in patients with HIV infection. Recommendations for the discontinuation of OI prophylaxis; Screening for hepatitis C virus (HCV) infection with anti-HCV enzyme;...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics